Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

Bergmann, L. and Berns, B. and Dalgleish, A. G. and von Euler, M. and Hecht, T. T. and Lappin, G. L. and Reed, N. and Palmeri, S. and Smyth, J. and Embacher-Aichorn, S. and Zwierzina, H. (2010) Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Annals of Oncology, 21 (8). pp. 1573-1578. ISSN 0923-7534

Full content URL: http://dx.doi.org/10.1093/annonc/mdq018

Full text not available from this repository.

Item Type:Article
Item Status:Live Archive

Abstract

Background: Drug development traditionally has relied upon the complementary contributions of clinicians and scientists at academic institutions and at pharmaceutical companies. Greater regulatory burdens, increased bureaucratic requirements, restricted reimbursement, and spiralling research and development costs are exerting pressure on the drug development pipeline. The result is a de-emphasis of exploratory research, particularly independent academic research, despite its proven value in identifying new drug targets and developing innovative cancer therapies. Design: An expert panel assembled by the Biotherapy Development Association-a nonprofit international forum for academic and industry researchers, patients, and government regulatory and postregulatory agencies-examined the growing schism between academia and industry and identified several causes of declining academic research. Results: The authors propose solutions to sustain investigator-initiated research and provide a new model whereby expert organisations provide a forum for academia and industry to plan studies within a regulatory framework to support licensure/authorisation and reimbursement for new molecularly targeted agents and biomarkers. Conclusions: Investigator-initiated trials have led to the discovery and development of innovative, safe, and effective cancer treatments. To ensure that such research continues, action will be required on the parts of legislative and regulatory bodies, industry, universities, patient advocacy organisations, and preclinical and clinical academic scientists. © The Author 2010. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Keywords:antineoplastic agent, biological marker, dendritic cell vaccine, provenge, cancer immunotherapy, cancer therapy, cell therapy, clinical study, drug design, drug efficacy, drug industry, drug quality, drug research, drug safety, drug screening, financial management, health care policy, human, priority journal, prostate cancer, review, T lymphocyte, Antineoplastic Agents, Clinical Trials as Topic, Humans, Neoplasms, Research Personnel
Divisions:College of Science > School of Pharmacy
Related URLs:
ID Code:8218
Deposited On:24 Mar 2013 21:25

Repository Staff Only: item control page